Immunotherapies direct the body’s own immune system to identify and destroy cancer cells and are revolutionizing cancer treatment. In recent years, advancements in immuno-oncology have seen the development of antibodies targeting checkpoint pathways that can inhibit T cell exhaustion or reawaken exhausted T cells leading to more effective tumor killing, and even antibodies that can increase the engagement of immune and tumor cells stimulating killing by direct cytotoxicity or phagocytosis.
Cell engineering approaches to create T cells and NK cells that seek and destroy cancer present vast therapeutic potential, with T cell-based therapies already receiving regulatory approval. Therefore, a deeper understanding of immune/tumor cell interactions and processes leading to cancer cell eradication is critical to identify and validate new targets and therapeutic approaches.
In this upcoming SelectScience webinar, Dr. John O'Rourke, from Sartorius, will illustrate the use of advanced high-throughput flow cytometry to detect immune cell cytotoxicity with a variety of applications and model immunotherapeutics. Further focus is given to sample miniaturization and novel data visualizations to accelerate the time to actionable results.
Attend the webinar to learn about:
The live webinar takes place on Monday, September 23, 2019, at:
Who should attend:
Scientists and executives in biotechnology, pharmaceuticals and academia should attend.
Certificate of attendance
All webinar participants can request a certificate of attendance, and a learning outcomes summary document for continuing education purposes.
Scheduling conflict? No matter, register to receive an on-demand link to watch later>>